Flubromazolam is a triazolobenzodiazepine, which are benzodiazepine derivatives. Flubromazolam is reputed to be highly potent, and concerns have been raised that clonazolam and flubromazolam in particular may pose comparatively higher risks than other designer benzodiazepines, due to their ability to produce strong sedation and amnesia at oral doses of as little as 0.5 mg
Flubromazolam is just one example of a designer benzodiazepine marketed on Internet shops as a research chemical. Although it is available for purchase, it is not a prescription product regulated by the US Food and Drug Administration. Flubromazolam has yet to be classified as a controlled substance in the United States at the federal level. The only state to classify it as a Schedule I controlled substance is Virginia.
Designer psychoactive substances have become popular drugs of abuse in recent years. Flubromazolam is a designer benzodiazepine with strong and long-lasting central nervous system depressive effects that increases the risk of life-threatening consequences.
Flubromazolam, renamed Flubber by some users after the 1997 Robin Williams film, has never been subject to a clinical trial.
It is described by WHO as similar to other street valium like Etizolam but “with a very high potency and long-lasting depressive effects of the nervous system”.
July 26, 2023 – DEA Temporary Placement of Etizolam, Flualprazolam, Clonazolam, Flubromazolam, and Diclazepam in Scedule I. Read the full announcement here.